Reply to 'Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial'

被引：0

作者：

O'Hagan, Justin J. ^{[1
,2
]}

Hernan, Miguel A. ^{[1
,3
]}

Walensky, Rochelle P. ^{[4
,5
,6
,7
]}

Lipsitch, Marc ^{[1
,2
,7
]}

机构：

[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA

[2] Harvard Univ, Sch Publ Hlth, Ctr Communicable Dis Dynam, Boston, MA 02115 USA

[3] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA

[4] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA

[5] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA 02114 USA

[6] Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA

[7] Harvard Univ, Sch Publ Hlth, Dept Immunol, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1097/QAD.0b013e328355cf0f

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2262 / 2263

页数：2